Winter 2000
Page 1 to 7 of 7 |
Putting the code to work: the promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Winter 2000
Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready to enter development?

Read More

HTS where next? By Dr Mark Beggs Winter 2000
After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world – the resolution of which will significantly affect the path along which the HTS discipline will develop.

Read More

Do venture capitalists act as gatekeepers of new technology? By Dr June Grindley and Samantha Smart Winter 2000
article discusses the important role that venture capitalists and others play in helping to create companies around new technologies. We asked a number of venture capitalists, when considering funding a new company, what was most important to them – people or science. We also asked whether they knew of technology that, without their sponsorship wouldn’t have been exploited.

Read More

The genie in the test tube – from gene to gene therapy: part II By Dr Jan Steiner Winter 2000
In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of gene therapy have been in inborn errors of metabolism, cancer, cardiovascular and central nervous system degenerative disease and transplantation and graft versus host disease. However, it would seem that this list is set to grow as understanding of the fundamental causes of disease and of delivery mechanisms for gene therapy become better understood.

Read More

High-throughput CRYSTALLISATION By Dr Sara Moran and Dr Lance Stewart Winter 2000
With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process?

Read More

DRUG DELIVERY adding value to drug development and commercialisation By Dr Cornelis ‘Cees’ Winnips Winter 2000
The importance of drug delivery as a tool to improve R&D productivity, to provide a pathway for valuable drugs to be successfully commercialised and as an expanding resource to the pharmaceutical and biotech industry, has come a long way since the early work of the University of Kansas. This article explores the advances made in drug delivery technology.

Read More

DISCOVERY RESEARCH IN THE CO-GENOMIC ERA biology goes industrial By Dr Timothy Wells and Dr Georg Feger Winter 2000
The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will go to the most creative entrepreneurs who can pull the technologies and knowledge together well enough to identify the rich prizes within.

Read More

Winter 2000
Page 1 to 7 of 7 |